IP Library Granted Patent US 12,478,680
Granted Patent B2
US 12,478,680 · App. 17/930,381 · Granted Nov 25, 2025

Hydrogels with biodegradable crosslinking

Inventors: Gary W. Ashley (Alameda, CA); Daniel V. Santi (San Francisco, CA); Jeffrey C. Henise (San Francisco, CA)
Assignee: ProLynx LLC
A61K47/34A61K9/06A61K47/30A61K47/50A61K47/60A61K47/61A61K47/6903A61L15/26A61L15/44A61L15/60A61L15/64A61L27/18A61L27/52A61L27/54A61L27/58C07C271/08C07C317/18C08J3/075C09B23/0025C09B23/0033C09B23/0066C09B23/0075G02F1/3611G02F1/3612G02F1/3614G02F1/3615C08G2650/30C08J2300/16C08J2305/08C08J2371/02Y10T428/261
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,478,680
App. No.
17/930,381
Granted
Nov 25, 2025
Kind
B2
Abstract

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

Claims (79)

1 . A hydrogel that is biodegradable under physiological conditions, wherein the hydrogel comprises one or more hyaluronic acid polymers crosslinked by a linker that decomposes by a beta elimination reaction,

wherein said linker is of Formula (1):

wherein for each linker of formula (1):

m of formula (1) is 0 or 1;

X of formula (1) is

wherein

T* is O, S, or NR 6 , wherein R 6 is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, or optionally substituted heteroarylalkyl;

z is 1-6;

Y is (OCH 2 CH 2 ) p , wherein p is 1-100; and

Z 2 is a first functional group that is coupled to a first cognate functional group on a hyaluronic acid polymer;

one of R 1 , R 2 , or R 5 comprises a second functional group that is coupled to a second cognate functional group on a hyaluronic acid polymer,

wherein each said first functional group and said second functional group comprises N 3 , NH 2 , NH—CO 2 t Bu, SH, S t Bu, maleimide, CO 2 H, CO 2 t Bu, 1,3-diene, cyclopentadiene, furan, alkyne, cyclooctyne, acrylate, or acrylamide;

with the proviso that:

(1) when one of R 5 of formula (1) comprises a second functional group that is coupled to a second cognate group of a hyaluronic acid polymer, the remaining R 5 of formula (1) is H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, (OCH 2 CH 2 ) p O-alkyl wherein p=1-1000, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl: and

(a) R 1 and R 2 of formula (1) are independently CN, NO 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, COR 3 , SOR 3 , SO 2 R 3 , or SR 4 ;

(b) R 1 and R 2 of formula (1) may be joined to form a 3-8 membered ring;

(c) R 1 of formula (1) is CN, NO 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, COR 3 , SOR 3 , SO 2 R 3 , or SR 4 ; and R 2 of formula (1) is H, optionally substituted alkyl, optionally substituted arylalkyl, or optionally substituted heteroarylalkyl; or

(d) R 2 of formula (1) is CN, NO 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, COR 3 , SOR 3 , SO 2 R 3 , or SR 4 ; and R 1 of formula (1) is H, optionally substituted alkyl, optionally substituted arylalkyl, or optionally substituted heteroarylalkyl; or

(2) when R 1 of formula (1) comprises a second functional group that is coupled to a second cognate group of a hyaluronic acid polymer: R 2 of formula (1) is CN, NO 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, COR 3 , SOR 3 , SO 2 R 3 , or SR 4 ; and each R 5 of formula (1) is independently H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, (OCH 2 CH 2 ) p O-alkyl wherein p=1-1000, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; or

(3) when R 2 of formula (1) comprises a second functional group that is coupled to a second cognate group of a hyaluronic acid polymer: R 1 of formula (1) is CN, NO 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, COR 3 , SOR 3 , SO 2 R 3 , or SR 4 ; and each R 5 of formula (1) is independently H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, (OCH 2 CH 2 ) p O-alkyl wherein p=1-1000, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl;

wherein

R 3 is selected from the group consisting of (i) H; (ii) optionally substituted alkyl; (iii) optionally substituted aryl; (iv) optionally substituted arylalkyl; (v) optionally substituted heteroaryl; (vi) optionally substituted heteroarylalkyl; (vii) OR 9 ; and (viii) NR 9 2 ;

R 4 is selected from the group consisting of (i) optionally substituted alkyl; (ii) optionally substituted aryl; (iii) optionally substituted arylalkyl; (iv) optionally substituted heteroaryl; and (v) optionally substituted heteroarylalkyl; and

each R 9 is independently H or optionally substituted alkyl, or both R 9 groups taken together with the nitrogen to which they are attached form a heterocyclic ring.

2 . The biodegradable hydrogel of claim 1 , wherein each said first functional group and said second functional group comprises N 3 .

3 . The biodegradable hydrogel of claim 1 , wherein in Formula (1):

m is 0.

4 . The biodegradable hydrogel of claim 1 , wherein in Formula (1):

R 2 is H;

one of R 5 is H; and

the other R 5 is (CH 2 ) n Z, wherein n is 1-6 and Z includes said second functional group.

5 . The biodegradable hydrogel of claim 4 , wherein n is 5.

6 . The biodegradable hydrogel of claim 1 , wherein in Formula (1):

R 1 is CN or SO 2 R 3 .

7 . The biodegradable hydrogel of claim 6 , wherein in Formula (1):

R 1 is SO 2 Ph.

8 . The biodegradable hydrogel of claim 1 , wherein in X of Formula (1):

T* is O, S, or NR 6 , wherein R 6 is H;

z is 1-6; and

Y is (OCH 2 CH 2 ) p , wherein p is 1-100.

9 . The biodegradable hydrogel of claim 1 , wherein the coupling of the first functional group with the first cognate group and the coupling of the second functional group with the second cognate group each comprises a product of:

a reaction of N 3 with acetylene, cyclooctyne, or maleimide;

a reaction of SH with maleimide, acrylate, acrylamide, vinylsulfone, vinylsulfonamide, or halocarbonyl;

a reaction of NH 2 with carboxylic acid or activated carboxylic acid; or

a reaction of maleimide with 1,3-diene, cyclopentadiene, or furan.

10 . The biodegradable hydrogel of claim 1 , wherein the coupling of the first functional group with the first cognate group and the coupling of the second functional group with the second cognate group each comprises a product of a reaction of N 3 with cyclooctyne.

11 . The biodegradable hydrogel of claim 1 , wherein:

each first functional group and second functional group comprises N 3 ;

m of formula (1) is 0;

X of formula (1) is

wherein

T* is NR 6 , wherein R 6 is H;

Y is (OCH 2 CH 2 ) 3 ; and

Z 2 is the first functional group and is N 3 ;

R 1 of formula (1) is SO 2 R 3 , wherein R 3 is aryl;

R 2 of formula (1) is H;

one of R 5 of formula (1) is H; and

the other R 5 of formula (1) is (CH 2 ) 5 Z, wherein Z is the second functional group and is N 3 .

12 . The biodegradable hydrogel of claim 1 , wherein:

each first cognate functional group and second cognate functional group of the hyaluronic acid polymer comprises cyclooctyne;

m of formula (1) is 0;

X of formula (1) is

wherein

T* is NR 6 , wherein R 6 is H;

z is 2;

Y is (OCH 2 CH 2 ) 3 ; and

Z 2 is the first functional group and is N 3 ;

R 1 of formula (1) is SO 2 Ph;

R 2 of formula (1) is H;

one of R 5 of formula (1) is H; and

the other R 5 of formula (1) is (CH 2 ) 5 Z, wherein Z is the second functional group and is N 3 .

13 . The biodegradable hydrogel of claim 11 , wherein z is 2.

14 . The biodegradable hydrogel of claim 11 , wherein R 3 is phenyl.

15 . The biodegradable hydrogel of claim 11 , wherein z is 2; and R 3 is phenyl.

16 . The biodegradable hydrogel of claim 1 , wherein:

one of R 5 of formula (1) comprises a second functional group that is coupled to a second cognate group of a hyaluronic acid polymer;

the remaining R 5 of formula (1) is H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, (OCH 2 CH 2 ) p O-alkyl wherein p=1-1000, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl:

R 1 of formula (1) is CN, NO 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, COR 3 , SOR 3 , SO 2 R 3 , or SR 4 ; and

R 2 of formula (1) is H, optionally substituted alkyl, optionally substituted arylalkyl, or optionally substituted heteroarylalkyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2025
From: ASHLEY, GARY W.; SANTI, DANIEL V.; HENISE, JEFFREY C.
To: PROLYNX LLC
Reel/Frame 071331/0659 →
Continuity (5)
Continuation 16557243 · Aug 30, 2019
Division 15486215 · Apr 12, 2017
Continuation 14343819
Provisional Application 61531990 · Sep 7, 2011
Related Publication 20230135347A1 · May 4, 2023
References Cited (30)
US 6258898B1 · Rehfuss et al. · 2001 [cited by applicant]
US 8946405B2 · Ashley et al. · 2015 [cited by applicant]
US 9649385B2 · Ashley et al. · 2017 [cited by applicant]
US 10398779B2 · Ashley et al. · 2019 [cited by applicant]
US 11179470B2 · Ashley et al. · 2021 [cited by applicant]
US 11181803B2 · Ashley et al. · 2021 [cited by applicant]
US 11454861B2 · Ashley et al. · 2022 [cited by applicant]
US 20050143484A1 · Fang et al. · 2005 [cited by applicant]
US 20060171920A1 · Schechter et al. · 2006 [cited by applicant]
US 20090269406A1 · Panitch et al. · 2009 [cited by applicant]
US 20100240586A1 · Bao et al. · 2010 [cited by applicant]
US 20100267895A1 · Harris et al. · 2010 [cited by applicant]
WO WO2006003014 · 2006 [cited by applicant]
WO WO2009095479 · 2009 [cited by examiner]
WO WO2009158668 · 2009 [cited by examiner]
WO WO2010059883 · 2010 [cited by applicant]
WO WO2011140376 · 2011 [cited by applicant]
WO WO2011140392 · 2011 [cited by applicant]
WO WO2011140393 · 2011 [cited by applicant]
Cadee, et al., “Release of recombinant human interleukin-2 from dextran-based hydrogels,” J Control Release (2002) 78:1-13. [cited by applicant]
Doxorubicin, The Myeloma Beacon, Published Oct. 15, 2008, Retreived from the Internet <URL: https://myelomabeacon.org/resources/2008/10/15/doxorubicin/>, 5 pages. [cited by applicant]
Hennink, et al., “Novel crosslinking methods to design hydrogels,” Adv Drug Del Rev (2002) 54:13-36. [cited by applicant]
Hoffman, “Hydrogels for biomedical applications,” Adv Drug Del Rev (2002) 54:3-12. [cited by applicant]
International Preliminary Report on Patentability and Written Opinion for PCT/US2012/054278, dated Mar. 12, 2014, 11 pages. [cited by applicant]
International Search Report for PCT/US2012/054278, mailed Jan. 17, 2013, 4 pages. [cited by applicant]
Jeong, et al., “Thermogelling biodegradable copolymer aqueous solutions for injectable protein delivery and tissue engineering,” Biomacromolecules (2002) 3(4):865-868. [cited by applicant]
Lyu et al., “Degradability of polymers for implantable biomedical devices,” Int J Mol Sci (2009) 10(9):4033-4065. [cited by applicant]
Sawhney et al., “Bioerodible hydrogels based on photopolymerized poly(ethyleneglycol)-co-poly(a-hydroxy acid) diacrylate macromers,” Macromolecules (1993) 26:581-587. [cited by applicant]
Supplementary European Search Report for EP 12829900.5, issued Apr. 26, 2016, 7 pages. [cited by applicant]
Surini, et al., “Release phenomena of insulin from an implantable device composed of a polyion complex of chitosan and sodium hyaluronate,” J Control Release (2003) 90(3):291-301. [cited by applicant]
Cited By (1)
US 12,697,395